- Home
- KMPR vs ICUI Comparison
KMPR vs ICUI Comparison
Compare KMPR & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMPR
- ICUI
- Stock Information
- Founded
- KMPR 1990
- ICUI 1984
- Country
- KMPR United States
- ICUI United States
- Employees
- KMPR N/A
- ICUI N/A
- Industry
- KMPR Property-Casualty Insurers
- ICUI Medical/Dental Instruments
- Sector
- KMPR Finance
- ICUI Health Care
- Exchange
- KMPR Nasdaq
- ICUI Nasdaq
- Market Cap
- KMPR 3.8B
- ICUI 3.5B
- IPO Year
- KMPR N/A
- ICUI 1992
- Fundamental
- Price
- KMPR $64.27
- ICUI $138.30
- Analyst Decision
- KMPR Strong Buy
- ICUI Strong Buy
- Analyst Count
- KMPR 4
- ICUI 5
- Target Price
- KMPR $78.25
- ICUI $196.75
- AVG Volume (30 Days)
- KMPR 536.7K
- ICUI 274.8K
- Earning Date
- KMPR 05-07-2025
- ICUI 05-08-2025
- Dividend Yield
- KMPR 2.00%
- ICUI N/A
- EPS Growth
- KMPR N/A
- ICUI N/A
- EPS
- KMPR 5.35
- ICUI N/A
- Revenue
- KMPR $4,687,400,000.00
- ICUI $2,420,093,000.00
- Revenue This Year
- KMPR $9.33
- ICUI $0.84
- Revenue Next Year
- KMPR $11.79
- ICUI $2.91
- P/E Ratio
- KMPR $11.68
- ICUI N/A
- Revenue Growth
- KMPR N/A
- ICUI 7.22
- 52 Week Low
- KMPR $53.57
- ICUI $95.44
- 52 Week High
- KMPR $73.01
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- KMPR 62.63
- ICUI 49.24
- Support Level
- KMPR $60.23
- ICUI $131.73
- Resistance Level
- KMPR $60.06
- ICUI $142.00
- Average True Range (ATR)
- KMPR 1.71
- ICUI 6.49
- MACD
- KMPR 0.87
- ICUI 0.67
- Stochastic Oscillator
- KMPR 97.25
- ICUI 57.04
About KMPR Kemper Corporation
Kemper Corp is a diversified insurance company that provides services in property and casualty insurance, along with life and health insurance. The company's property and casualty segment offers personal and commercial lines for home and automotive products. The company conducts its operations through two operating segments: Specialty Property & Casualty Insurance, and Life Insurance.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.